Pacira BioSciences, Inc. (PCRX) Stock
PCRX has an Alpha Score of 38 out of 100 (weak), computed on Nov 5, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 9 trades in PCRX since 2019: 9 purchases and 0 sales, most recently Tom Malinowski (purchase, May 6, 2021). 6 of the hedge funds AlphaScala tracks reported PCRX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $49.48M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 99.1 and its net margin 2.0% (key statistics as of Oct 29, 2026).
What is PCRX's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with strong momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Pacira BioSciences, Inc. (PCRX)?
Most recent: Tom Malinowski (purchase, May 6, 2021); records start May 30, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tom Malinowski D-NJ · House | 2021-05-06 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-04-20 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-01-25 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2021-01-15 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2020-11-02 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2019-09-26 | purchase | $15k – $50k |
| Tom Malinowski D-NJ · House | 2019-08-23 | purchase | $1k – $15k |
| Tom Malinowski D-NJ · House | 2019-05-31 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all PCRX political trades →Which hedge funds own PCRX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.95M | $49.48M | -2% |
| Renaissance Technologies Jim Simons (founder) | 1.73M | $43.99M | -5% |
| Millennium Management Israel Englander | 235K | $5.97M | +312% |
| Citadel Ken Griffin | 162K | $4.11M | -80% |
| Marshall Wace | 129K | $3.28M | NEW |
| Hussman Investment Trust John Hussman | 42K | $1.05M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Pacira BioSciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 8, 26 | Riker Lauren | Senior Vice President, Finance | SELL | 6.0K | $218K |
| Aug 17, 26 | Slonin Jonathan | Chief Medical Officer | SELL | 3.0K | $71K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are PCRX's key statistics?
Key statistics as of Oct 29, 2026
How does PCRX's valuation compare with the Healthcare sector?
| Metric | PCRX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 99.1 | 28.8 | 111 |
| Net margin | 1.96% | 4.31% | 164 |
| Return on equity | 2.13% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
PCRX price chart
Powered by TradingViewWhat does Pacira BioSciences, Inc. do?
Pacira BioSciences Inc. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative non-opioid pain management therapies. Its primary focus is transforming patient care by providing opioid-sparing alternatives for acute, postsurgical, chronic, and musculoskeletal pain, including commercial products like EXPAREL (bupivacaine liposome injectable suspension) for long-acting local analgesia and iovera, which delivers precise cryoneurolysis to targeted nerves. The company advances solutions across the neural pain pathway, from pre-surgical preparation to rehabilitation, emphasizing enhanced recovery protocols that minimize opioid reliance. Pacira BioSciences Inc. also pursues pipeline innovations such as PCRX-201, a gene therapy candidate designed for local injection to boost IL-1Ra production and reduce chronic inflammation in osteoarthritis of the knee. Serving hospitals, ambulatory surgery centers, healthcare practitioners, and patients, the company prioritizes patient safety, rigorous quality controls, and ethical standards in research, manufacturing, and marketing. Headquartered in Tampa, Florida, Pacira BioSciences Inc. leads the shift toward non-opioid standards in pain management.